Pharmaceuticals, Biotechnology and Life Sciences
Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, has reported its full-year 2016 results.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has reported its final results for the year ended 31 December 2016.
US Food and Drug Administration (FDA) has accepted the Novertis’s Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL).
U.S. Food and Drug Administration (FDA) has approved Roche’s subsidiary Genentech’s Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
Faron Pharmaceuticals, the clinical stage biopharmaceutical company, has reported full year audited results for the year ended 31 December 2016.
Allergy Therapeutics, the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2016.
Alliance Pharma, the specialty pharmaceutical company, has announced results for the year ended 31 December 2016.
The Executive Board of Stada Arzneimittel AG has published the final figures for financial year 2016 which are, due to the revaluation of a transaction, diferent from the preliminary figures which the company had already published on March 1, 2017.
A medical diagnostics company focused on allergy, food intolerance and infectious disease, Omega, has CE-Marked its Visitect range of Malaria tests.
European Medicines Agency (EMA) has granted orphan designation to AstraZeneca’s and MedImmune’s inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).